GH vs. CDNA, FLGT, PSNL, GTH, BNR, NTRA, FMS, OPCH, PACS, and HIMS
Should you be buying Guardant Health stock or one of its competitors? The main competitors of Guardant Health include CareDx (CDNA), Fulgent Genetics (FLGT), Personalis (PSNL), Genetron (GTH), Burning Rock Biotech (BNR), Natera (NTRA), Fresenius Medical Care (FMS), Option Care Health (OPCH), PACS Group (PACS), and Hims & Hers Health (HIMS).
Guardant Health (NASDAQ:GH) and CareDx (NASDAQ:CDNA) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their community ranking, analyst recommendations, dividends, institutional ownership, profitability, risk, media sentiment, valuation and earnings.
CareDx has lower revenue, but higher earnings than Guardant Health. Guardant Health is trading at a lower price-to-earnings ratio than CareDx, indicating that it is currently the more affordable of the two stocks.
Guardant Health has a beta of 1.13, indicating that its share price is 13% more volatile than the S&P 500. Comparatively, CareDx has a beta of 1.78, indicating that its share price is 78% more volatile than the S&P 500.
In the previous week, Guardant Health had 7 more articles in the media than CareDx. MarketBeat recorded 13 mentions for Guardant Health and 6 mentions for CareDx. CareDx's average media sentiment score of 0.92 beat Guardant Health's score of 0.82 indicating that CareDx is being referred to more favorably in the news media.
92.6% of Guardant Health shares are owned by institutional investors. 5.5% of Guardant Health shares are owned by company insiders. Comparatively, 4.2% of CareDx shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Guardant Health currently has a consensus target price of $37.38, indicating a potential upside of 13.29%. CareDx has a consensus target price of $17.00, indicating a potential downside of 10.57%. Given Guardant Health's stronger consensus rating and higher possible upside, analysts plainly believe Guardant Health is more favorable than CareDx.
CareDx has a net margin of -66.59% compared to Guardant Health's net margin of -76.34%. CareDx's return on equity of -55.08% beat Guardant Health's return on equity.
CareDx received 161 more outperform votes than Guardant Health when rated by MarketBeat users. However, 69.23% of users gave Guardant Health an outperform vote while only 66.31% of users gave CareDx an outperform vote.
Summary
Guardant Health beats CareDx on 10 of the 18 factors compared between the two stocks.
Get Guardant Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for GH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Guardant Health Competitors List
Related Companies and Tools
Free GH Stock Alerts